Independent sources. Study context first. Community claims kept separate.
50
Catalog entries
88
Study / official links
10
Product evidence gaps
Candidate findings, not approved catalog additions
Research use only. These sources do not validate existing dosing fields, community schedules or supplier vials. A human study may concern a different disease, formulation or route. This targeted search is not an exhaustive review; some full methods remain unverified. Community links are provenance leads, not recommendations.
Editorial standards50 of 50 entries
Original laboratory study with publisher methods: rat Achilles explants/fibroblasts; outgrowth, migration, oxidative-stress survival, FAK/paxillin phosphorylation.
Preclinical, not a human tendon-repair protocol. Replaces reliance on dossier reviews with an original experiment; does not establish human efficacy, systemic safety or product purity.
Analytical characterization is not a treatment trial. Registries describe a trial in 72 adults with venous stasis ulcers, topical synthetic 43-residue full-length Tβ4, safety/tolerability and ulcer healing. US/EU entries describe the same SSVS study, not independent replication.
Human full-length Tβ4 research must not be relabeled fragment efficacy. No controlled human fragment-repair protocol identified. Sequence and analytical identity must precede attribution; neither registry establishes equivalence of research vials.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
Four phase 3 randomized controlled trials of adults with overweight/obesity, with/without diabetes; weight-change endpoints, lifestyle cointervention. Existing SURMOUNT-1 demonstrated substantial weight loss. Exact GIP/GLP-1 dual agonist, not retatrutide or a combination vial.
Yes: dedicated design paper, distinct from SURMOUNT-1/ SURPASS-2/ SURMOUNT-5 already cited. Lilly-associated; not sponsor-independent. GI events and discontinuation; selected trial populations and product quality restrict generalization.
LY3437943, single triple GIP/GLP-1/glucagon agonist. TRIUMPH describes four randomized double-blind phase 3 trials across obesity, OSA, knee OA and cardiovascular-disease populations. The phase 2 trial in 338 adults showed weight reduction; the program-design publication is not phase 3 success evidence.
Yes: dedicated program-design publication, with nested disease protocols described, not a substitute for every complete protocol attachment. Lilly-led; no independent replication established here. GI events and heart-rate increases in the phase 2 trial; long-term benefit/risk and research-vial equivalence unestablished.
Randomized phase 3 obesity program, adults with/without diabetes depending on trial; weight change and safety endpoints. STEP 1 established weight reduction. Study-specific pharmaceutical semaglutide, not interchangeable evidence for oral formulations, salts, or supplier vials.
Yes: published program-design paper, not itself a full signed trial protocol or new efficacy result. GI intolerance and retinopathy concerns in diabetes require indication-specific interpretation; long-term rare harms cannot be inferred from a design paper. Novo Nordisk involvement; not independent replication.
Located human DAC-CJC-1295 study is single-agent GH/IGF-1 research, not the mixture. No exact premixed no-DAC pair study located.
Catalog explicitly says no DAC; Teichman studied long-acting DAC CJC-1295. Existing dossier correctly acknowledges mismatch but still places component outcomes under blend findings; label them component-only.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
Published phase 2 postoperative bowel-resection trial: 117 enrolled, 114 in safety/modified-ITT populations; key and secondary efficacy analyses were not significantly different from placebo. Raun research concerns animal and pituitary-cell GH responses.
Human experience exists, but GI recovery is not evidence for muscle gain, chronic GH optimization or catalog presentations. Animal ACTH/cortisol selectivity does not establish a human safety advantage. Publication methods beyond indexed record were not fully audited.
Multicenter randomized evaluator-blinded vehicle-controlled study of topical lamin Gel in diabetic neuropathic ulcers; ulcer closure and infections in a standardized wound-care context. Fibroblast study measures collagen synthesis.
Stronger original topical evidence than cosmetic-review summaries alone, but not injectable evidence. Product, disease, vehicle and concomitant wound care limit generalization. No controlled systemic injectable benefit/safety protocol identified. Abstract/publisher record verified, not a complete modern protocol package.
Original telomerase/telomere study in human fetal fibroblast culture; author-hosted published full paper gives experimental methods.
AEDG tetrapeptide, not Epithalamin/Epithalamine animal pineal peptide extract, from whose composition it was designed. Existing dossier is review-heavy plus a newer cell study; the original full paper is a useful methods anchor. Cell telomerase activation does not demonstrate human life extension; extract-based clinical claims cannot be transferred.
Synthetic native mitochondrial 16-aa peptide in mice and cell experiments; improved mouse physical capacity/metabolic adaptation. Human component measured endogenous exercise-associated MOTS-c, not therapeutic administration. Modified analogues such as CB4211 cannot validate native MOTS-c.
No separate therapeutic human protocol identified; genuine experimental methods in results papers. New paper is overlapping investigator-network work, not independent replication. Rodent performance is not human obesity efficacy; human pharmacology, immunogenicity and long-term safety remain gaps.
Rat hippocampal BDNF/TrkB and conditioned-avoidance experiment; separate clinical stroke-rehabilitation study.
MEHFPGP Semax, not Adamax or acetylated/amidated analogues. Existing citations match these contexts, but healthy-human focus enhancement and supplier injectable presentations are not established by them. Full rat paper is subscription-linked; indexed clinical abstract does not establish all allocation/blinding details.
Small comparative clinical anxiety/neurasthenia study, and IMR-32 cell qPCR experiment.
Selank, not modified “NA-Selank” analogues. Filatova reports no direct Selank-alone change in the studied GABAergic-system gene mRNA levels; changes in combination experiments must not become a blanket Selank-alone gene-expression claim. Anxiety endpoints are not healthy-person cognitive enhancement. Full clinical methods not verified; cell full text available.
Original retrospective knee-pain series contacted 16 of 17 patients; four had BPC-157 + TB4. Telephone follow-up without a control group or validated functional measures does not establish efficacy of this supplier’s premixed vial.
TB4 in that report cannot automatically be equated to catalog TB-500. Analytical literature identifies TB-500 as acetylated Tβ4 residues 17–23; supplier terminology varies. Premix stability/composition equivalence remains unestablished. The linked Medvinci report names Thymosin Beta-4, without resolving sequence equivalence, and its reported sample content differs from the 10 mg + 10 mg label. Independent certificate authentication and purchased-lot linkage remain unconfirmed.
No original exact three-component mixture experiment located. Identified commercial/community blend index is provenance only.
Free GHK versus copper complex, TB-500 fragment versus full-length Tβ4, ratios and formulation need verification. No dedicated dossier; catalog appropriately warns against ingredient extrapolation. No mixture stability, pharmacokinetics, controlled safety or efficacy source located.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
No original exact four-component mixture experiment located.
Adding KPV creates a different intervention from GLOW; ingredient anti-inflammatory results cannot validate this mixture. TB-500 identity remains unresolved at product level. No dedicated dossier or mixture methods/stability/clinical dataset located.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
Human HIV-associated abdominal adiposity trials: CT visceral fat, metabolic markers; separate HIV/NAFLD trial: liver-fat endpoints. Government label supplies formulation-specific indication and safety framework.
Approval is for specified branded formulations and HIV-associated lipodystrophy, not generic research vials or general weight loss. WR and SV are explicitly not substitutable. Historical Egrifta approval does not validate catalog presentations. Label warns about elevated IGF-, glucose intolerance/diabetes, fluid retention, hypersensitivity and malignancy concerns; long-term cardiovascular safety unestablished.
NNC0174-0833, long-acting acylated amylin analogue; randomized phase 2 weight-management study, registry enrollment 706. Weight reduction result is Lau 2021, already cited. CagriSema results already cited are combination evidence, not standalone efficacy estimates; REDEFINE 1 also included monotherapy comparators.
Yes: actual publicly posted protocol/amendments, plus separate statistical analysis plan, stronger protocol provenance than a registry synopsis. Sponsor Novo Nordisk; not independent replication. GI intolerance; limited duration, selected population, and investigational formulation do not establish supplier-vial safety.
Healthy-adult endocrine/pharmacokinetic studies: GH, IGF-, exposure and GH pulsatility. Indexed original study records; no additional independent primary study selected.
These studies concern DAC. “CJC-1295 no DAC” commonly denotes modified GRF(1–29), not the trial molecule; there is no separate qualifying no-DAC single entry. Do not transfer DAC duration, safety or efficacy to no-DAC products or blends. Small/short endocrine studies do not demonstrate repair or long-term clinical benefit.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
Direct oxidized nicotinamide adenine dinucleotide, not NADH, NR or NMN. Small healthy-male pilot (8 NAD+, 3 saline controls) examined plasma/urine metabolome: delayed circulating changes, metabolism and urinary excretion; not a weight-loss, longevity or clinical-function efficacy trial. Existing NADPARK/MCI citations are NR trials, not direct NAD+.
No separate prospective full protocol identified; original pilot has methods, not a validated treatment protocol. Clinic/NAD-industry affiliations require disclosure; not independent replication. Small cohort and brief observation cannot establish safety. FDA reports severe chills, shaking, vomiting and fatigue after compounded injectable NAD+, consistent with endotoxin contamination; food-grade inputs are not sterile-drug evidence.
Modified hGH C-terminal hexadecapeptide, Tyr-hGH(177–191), not intact hGH or every product called fragment 176–191. Six randomized placebo-controlled human trials summarized retrospectively, including oral/IV study settings; authors report no IGF-1/glucose impairment and favorable tolerability. This is not proof of obesity efficacy or safety of other routes/forms.
No standalone full clinical protocol identified. Safety synthesis has methods, but is not a prospective protocol and includes developer-affiliated authors. Small/selected antibody testing and historical study reporting limit reassurance; FDA flags peptide characterization/immunogenicity and insufficient safety information. Existing Wilding development review and sports-medicine review are not new discoveries.
5-amino-1-methylquinolinium small-molecule NNMT inhibitor, not a peptide. Biochemical/permeability assays, cultured adipocytes and diet-induced obese mice; reduced adiposity/weight measures. A series of related inhibitors is studied: do not assign every analogue result to 5-amino-1MQ or infer salt equivalence.
No separate human or standalone protocol identified; original paper contains experimental methods. Not a new citation discovery. Short mouse experiments and selectivity assays cannot establish chronic systemic safety, human effectiveness, or safe product formulation.
Acadesine/AICA riboside (nucleoside); intracellular ZMP is the phosphorylated active metabolite and is sometimes also called AICAR. Acute study: 6 young, 8 older and 8 T2D participants; muscle glucose uptake increased, blunted with age, without detected AMPK activation at sampled time point. Ex vivo tissue is not a treatment trial.
No separate standalone metabolic protocol identified; full experimental methods in original human results. Adds human mechanistic evidence beyond already cited Narkar mouse/Pold rat work, not weight-loss or exercise-replacement efficacy. Acute/small cohorts cannot resolve long-term safety; AMPK-only mechanism is oversimplified.
Vendor descriptions only located; no original published Adamax-specific pharmacology/methods study identified.
Listings describe acetylated/adamantane-modified Semax-related material, but one assigns CAS 114681-65-1 while another says no official CAS assigned. Vendor formula or HPLC percentage does not resolve exact structure, attachment chemistry or stereochemistry. Existing caution is appropriate; Semax findings cannot fill the evidence gap.
No exact-product published source identified in this search.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
Exact active-agent pair genuinely studied in original phase 3 REDEFINE ; registered randomized study and regulator/ethics protocol summary available.
Sponsor-manufactured CagriSema trial intervention does not validate the catalog premixed research vial, its excipients, stability, purity or bioequivalence. Do not assert all CagriSema trials used separate injections: REDEFINE 1 registry describes one injection. Add dedicated combination dossier; keep combination outcomes separate from cagrilintide monotherapy.
No original exact premixed pair study located. Teichman's CJC-1295-only human trial is not combination evidence.
Vendor page simultaneously describes DAC chemistry and says “DOES NOT CONTAIN DAC”; this illustrates why catalog naming is insufficient. Need exact GHRH-analogue sequence/modification documentation. No dedicated dossier; class-level GHRH/GHRP synergy cannot supply pair-specific efficacy or a protocol.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
No original exact-pair study located; Raun is ipamorelin-only animal/in-vitro work.
Neither single-agent tesamorelin clinical evidence nor GHRH/GHRP class synergy establishes this formulation. No dedicated dossier or mixture-specific safety/stability/efficacy methods located.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
No original exact three-agent study located. Identifiable comparison site makes body-recomposition claims; it is not a published research protocol.
Resolve CJC DAC status and exact AOD identity; four-component “Super Shredder” products are not this three-agent catalog mixture. No dedicated dossier or validated mixture efficacy, stability or safety source located.
No exact-product published source identified in this search.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
No original exact three-component study located.
BPC-157 + TB4 knee report lacks KPV and cannot substantiate Tri-Heal; TB4/TB-500 identity is additionally unresolved. No dedicated dossier; mixture claims and branded-name healing implications remain unsupported by an exact-mixture source.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
Human phase 2 randomized placebo-controlled sarcoidosis small-fiber neuropathy study: corneal nerve fibers, skin fibers, symptom/function measures and safety.
Disease-specific, short study; nerve morphology is not universal tissue-repair efficacy. Registry adds inspectable protocol provenance, not independent replication of the dossier's publication. No broad repair approval established.
Original RECONNECT randomized phase 3 HSDD trials; sexual desire/distress outcomes, not cognition.
Bremelanotide is not Melanotan II; research-vial equivalence to the trial product is unestablished. Existing primary citation is relevant to HSDD, not the catalog's cognitive goal. Published clinical methods are the appropriate source rather than a community protocol.
Original aging human embryo bone-marrow MSC gene-expression experiment; separate periodontal-ligament stem-cell differentiation experiment examining peptides and a mixture.
AED is not AEDG/Epitalon. The differentiation study's multi-peptide compound is not evidence for AED alone. Dossier acknowledges the mixture but cannot establish human longevity or cartilage efficacy. First source abstract checked; second supplies full methods.
Small double-blind matched-pairs study in chronic insomnia, with polysomnography and subjective measures; investigators judged effects weak and unlikely to provide major therapeutic benefit.
DSIP and Deltaran must be separated; the existing dossier's animal Deltaran result is not a DSIP-only clinical outcome. Add the direct human insomnia study instead of relying primarily on review/animal survival claims. Full methods publisher-linked but paywalled.
Original senescent-cell and mouse chemotoxicity/aging experiments; full methods and supplementary material available.
D-retro-inverso engineered peptide, not native FOXO4 protein or an arbitrary FOXO4 fragment; sequence/stereochemistry/construct identity matter. Existing original citation is a strong preclinical anchor; it is not a human longevity protocol or clinical safety dataset.
18 healthy men; acute endocrine experiment measuring GH, prolactin, cortisol, LH/TSH and interaction with GHRH.
Direct primary replacement for dossier's clinical review. GH response is not anabolic benefit; prolactin/cortisol responses undermine blanket selectivity claims. No chronic safety or athletic-outcome inference.
Original randomized placebo-controlled oral supplementation study in healthy adults measuring glutathione stores/immune biomarkers.
Reduced glutathione, oxidized forms, liposomal formulations and injectable presentations should not be treated as identical interventions. Existing oral citation is valid for biomarkers; it does not establish injected longevity benefit or survival benefit. Abstract methods checked; full paper still needed for detailed analytical procedures.
Original functional-expression screening and neuronal cell-death rescue experiments; full methods available.
Humanin and analogues such as HNG must be distinguished; the original paper shows structure-dependent activity. Existing dossier relies on reviews that combine humanin/analogue findings; add the original source and identify the exact peptide used in each later experiment. No human longevity benefit established by this cell experiment.
Recombinant analogues; rat-derived cell lines, receptor/binding-protein interactions, protein/DNA synthesis and proteolysis. Separate analytical report detected a His-tagged black-market variant.
Preclinical/analytical, not human therapeutic trial. Native IGF-I or mecasermin evidence is not LR3 evidence. No validated prolonged human half-life or human growth protocol identified; product variants and IGF-axis hypoglycemia/mitogenic concerns require caution rather than assumed safety.
Healthy men; acute reproductive-endocrine physiology: LH pulse frequency/amplitude and testosterone.
Primarily GnRH/LH axis, not a GH secretagogue: catalog goal is misleading. Full text adds accessibility, not new evidence. Small physiology study does not validate long-term endocrine enhancement or infertility outcomes.
Human epithelial/T-cell lines and mouse DSS/TNBS colitis; PepT1 transport, NF-κB/MAPK signaling, cytokines and histology.
Human cells are not human participants. Preclinical anti-inflammatory findings do not establish injectable repair efficacy. Engineered conjugates are not free KPV; no human clinical protocol identified here.
Original pilot phase 1 human pigmentation/sexual-effects study; separate qualitative analysis of online discussion forums.
MT-II is not bremelanotide or afamelanotide. Catalog cognitive tag lacks support from the selected clinical outcomes. The forum study is community-provenance research, not efficacy evidence or a validated usage protocol. Pilot abstract checked; full clinical methods not verified.
Original randomized placebo-controlled trial in children and adolescents with autism; no significant between-group improvement in the primary ABC modified Social Withdrawal score. Identity and results checked against the indexed abstract; full methods were not independently retrievable in this audit.
Intranasal study formulation and delivery are not interchangeable with a supplier vial or obstetric injection. Add this direct large trial to the existing meta-analysis-only dossier; neither autism treatment nor healthy-person cognitive enhancement follows from a general social-neuropeptide rationale.
Multicenter open-label study: 110 previously untreated prepubertal GH-deficient children; height velocity, bone age and biochemical safety. Regulatory record addresses historical branded-product withdrawal.
Pediatric GH deficiency is not adult anti-aging. Open-label design and efficacy-set exclusions limit inference. FDA found Geref was not withdrawn for safety/effectiveness reasons; this does not approve current compounded/research products. Better primary grounding than dossier review/editorial.
Synthetic small-molecule ERRα/β/γ agonist, not peptide, estrogen receptor agonist, or later SLU-series analogues. Cell/receptor work and mouse exercise response; diet-induced obese and ob/ob mice showed energy-expenditure/fat-oxidation effects and reduced fat accumulation.
No separate clinical protocol identified; chemistry and animal methods are in original results papers. Same research program, not independent replication. No human therapeutic efficacy, exposure or chronic safety established by these sources. Existing metabolic/heart-failure citations must not be relabeled new.
Mitochondria-targeted tetrapeptide, also MTP-131; specified pharmaceutical elamipretide is not proven equivalent to supplier SS-31. MMPOWER-3: 218 adults with primary mitochondrial myopathy, randomized placebo-controlled; no primary walking/fatigue benefit. FDA accelerated approval in September 2025 concerns Barth syndrome, not general metabolic/weight benefit.
Registry is not a full protocol; original results have methods, but no separate protocol file was verified in this audit. FDA approval is based on a surrogate muscle-strength measure with confirmatory benefit requirements, not reversal of the negative PMM trial. Injection-site reactions common. Approval itself was already noted in dossier prose; new FDA URL is corroboration, not discovery of the approval.
BI 456906, GLP-1/glucagon dual agonist, not retatrutide. Phase 3 randomized double-blind trials in obesity without T2D (726) and with T2D (755), weight and safety endpoints; design paper does not supply phase 3 efficacy. Existing phase 2 studies report weight loss and histological MASH improvement.
Yes: dedicated trial-design publication, not every complete signed protocol. Boehringer-sponsored, not independent replication. GI adverse events/discontinuation and different MASH versus obesity populations constrain interpretation; no vendor-form equivalence.
NS2330, small-molecule serotonin/noradrenaline/dopamine reuptake inhibitor; not peptide and not tesofensine+metoprolol combination (“Tesomet”). Phase 2 randomized double-blind obesity study with diet intervention; published weight reduction and separate mechanistic appetite study.
Registry only newly located; no independent standalone full protocol verified. Registry estimated enrollment 200 should not override published actual analyzed populations. The 2008 obesity publication carries a 2013 Lancet expression of concern. Cardiovascular/heart-rate/BP effects and psychiatric/interaction risks warrant caution; short trials do not establish long-term safety or supplier-formulation equivalence.
361 patients in published severe-sepsis RCT across six Chinese ICUs (registry enrollment 366); 28-day mortality and immune markers including monocyte HLA-DR.
Human immune/sepsis evidence, not musculoskeletal repair. Published study says single-blind, registry describes double masking: resolve from methods/history rather than merging claims. Primary mortality result was not conventionally significant; no blanket survival benefit. Dossier meta-analyses are not original protocols; no US approval inferred.
TESICO randomized severe-COVID respiratory-failure trial: intravenous aviptadil did not demonstrate significant clinical improvement at day 90 and was stopped for futility. This is pulmonary research, not cognition.
Synthetic VIP/aviptadil study formulation cannot be assumed equivalent to supplier VIP. TESICO must be considered alongside the earlier trial’s secondary survival signal; neither demonstrated a significant primary-endpoint benefit. No cognitive protocol was located, and pulmonary endpoints cannot substantiate one.
No original published exact-pair trial/protocol located. CagriSema is a different pair and cannot validate this stack.
Tirzepatide is not semaglutide; separate-vial use is also not a characterized coformulation. No dedicated dossier; no controlled stack safety/efficacy evidence located.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.
No original published exact-pair trial/protocol located.
Retatrutide is not semaglutide or tirzepatide; single-agent results and CagriSema cannot be imported. No dedicated dossier or controlled mixture safety/efficacy/stability methods located.
No exact-product published source identified in this search.
Unverified provenance only. Author independence and source originality are not established. Commercial interests may apply.